5L3A image
Entry Detail
PDB ID:
5L3A
Keywords:
Title:
Fragment-based discovery of 6-arylindazole JAK inhibitors
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2016-04-06
Release Date:
2016-04-27
Method Details:
Experimental Method:
Resolution:
1.98 Å
R-Value Free:
0.27
R-Value Work:
0.23
R-Value Observed:
0.23
Space Group:
C 1 2 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase JAK2
Mutations:Y1007F, Y1008F
Chain IDs:A
Chain Length:295
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.
Acs Med.Chem.Lett. 7 641 646 (2016)
PMID: 27326341 DOI: 10.1021/acsmedchemlett.6b00087

Abstact

Janus kinase (JAK) inhibitors are emerging as novel and efficacious drugs for treating psoriasis and other inflammatory skin disorders, but their full potential is hampered by systemic side effects. To overcome this limitation, we set out to discover soft drug JAK inhibitors for topical use. A fragment screen yielded an indazole hit that was elaborated into a potent JAK inhibitor using structure-based design. Growing the fragment by installing a phenol moiety in the 6-position afforded a greatly improved potency. Fine-tuning the substituents on the phenol and sulfonamide moieties afforded a set of compounds with lead-like properties, but they were found to be phototoxic and unstable in the presence of light.

Legend

Protein

Chemical

Disease

Primary Citation of related structures